Cerevance’s solengepras has met the primary endpoint in the Phase 3 ARISE trial, reducing daily Parkinson’s OFF time by 0.61 hours versus placebo while also improving ON time and daily motor function. The result validates a novel GPR6-based, non-dopaminergic approach, but the absolute effect was smaller than in Phase 2 and arrives just as AbbVie
Preliminary Phase 1 data showed brain exposure, a half-life above 30 hours and dose-dependent IL-1β inhibition for AC Immune’s oral NLRP3 inhibitor ACI-19764.
Renew Biotechnologies has published peer-reviewed proof-of-concept research showing that native cell-free DNA methylation sequencing can recover neuron-associated blood signals that differ across Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. The results strengthen the scientific rationale behind its NeuroLens platform, but the decisive next step is independent, prospective validation in larger and more diverse patient
Galmed’s Aramchol film may simplify Parkinson’s dosing, but clinical proof and regulatory clearance remain ahead. See what matters next.
See how Zambon’s Hopledo could change Parkinson’s motor fluctuation care in Europe after a positive CHMP opinion, and what risks remain.
Staged bilateral focused ultrasound reduced Parkinson’s motor complications without implanted hardware, but persistent speech, gait and balance effects narrow the patients most likely to benefit.
Parkinson’s drugs still treat symptoms. Acurex’s ASAP grant puts 15-lipoxygenase and ferroptosis into sharper disease-modifying focus.
Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.
Explore how BioVie Inc.’s bezisterim could reshape Parkinson’s treatment strategies ahead of Phase 2 data. Find out what it means for the industry.
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.